AstraZeneca boosts early respiratory medicine with Pieris deal

LONDON (Reuters) - AstraZeneca boosted its early-stage respiratory medicine pipeline on Wednesday by signing a deal with Pieris Pharmaceuticals to develop novel inhaled drugs that could fight asthma in new ways.